Cosmos Health Reports $2.27 Million in TTM Amazon UK Sales and Sets Out $3.9 Million Outlook
Cosmos Health reported a 90% increase in Amazon UK sales to £1.71 million, or approximately $2.27 million, for the trailing twelve months to November 2, 2026. The company also reported approximately $525,000 in channel-level net profit and expects sales of approximately $3.9 million over the next twelve months.
Cosmos Health Inc. (NASDAQ:COSM) reported that sales through its Amazon UK channel reached £1.71 million, or approximately $2.27 million, for the trailing twelve months from November 1, 2025 to November 2, 2026. The company said this represented an increase of 90% from approximately $1.19 million in the prior twelve-month period.
During the reported period, Cosmos Health said it sold 116,978 units to customers in the United Kingdom, equal to an average of approximately 320 units per day.
Monthly sales increased from approximately $144,000 in November 2025 to more than $215,000 in each month from July through October 2026. The company identified those four months as its strongest Amazon UK sales period to date.
Cosmos Health reported approximately £395,000, or approximately $525,000, in net profit from the Amazon UK channel. The figure represents an approximately 23% net margin after direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT.
Advertising costs accounted for 2.4% of trailing-twelve-month sales, while refunds remained below 1% of sales. Cosmos Health said the profit and margin figures are channel-level operating metrics calculated before corporate overheads and are not U.S. GAAP measures.
Cosmos Health expects Amazon UK sales to grow by approximately 72% over the next twelve months to approximately $3.9 million, or an average of approximately $325,000 per month. The company said this outlook is based on current sales trends and planned growth initiatives on the platform.
The sales outlook is forward-looking, and Cosmos Health stated that actual results may differ materially. The company also described Amazon UK as part of its transition to a high-margin business model and said it believes the channel's performance demonstrates the profitability its proprietary brands can achieve through online sales channels.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. Its activities include proprietary pharmaceutical and nutraceutical brands, manufacturing through Cana Laboratories S.A., pharmaceutical and parapharmaceutical distribution, research and development, and telehealth through ZipDoctor, Inc.
The reported sales, unit and profit figures are based on Cosmos Health's Amazon UK seller-platform data and are unaudited. The company said the figures may differ from amounts in its financial statements. U.S. dollar amounts were converted from British pounds sterling using the exchange rate as of the date of the release.
Cosmos Health announced an update on its Amazon UK business, reporting sales of £1.71 million, or approximately $2.27 million, for the trailing twelve months from November 1, 2025 to November 2, 2026. The Company also reported approximately $525,000 in channel-level net profit and an approximately 23% net margin after direct channel costs.
Cosmos Health announced the update on November 4, 2026. The reported results cover the trailing twelve months from November 1, 2025 to November 2, 2026, with comparisons made against the prior twelve-month period.
Cosmos Health reported that Amazon UK sales increased by 90% to approximately $2.27 million from approximately $1.19 million in the prior twelve-month period. The reported sales were £1.71 million when stated in pounds sterling.
Cosmos Health reported approximately £395,000, or approximately $525,000, in Amazon UK net profit after direct channel costs, representing an approximately 23% net margin. The Company said these costs included Amazon fees, cost of goods, shipping, advertising and VAT; the figures are channel-level operating metrics before corporate overheads and are not U.S. GAAP measures.
Cosmos Health reported selling 116,978 units to customers in the United Kingdom during the trailing twelve months, an average of approximately 320 units per day. The unit figures are based on the Company's Amazon UK seller platform data and are unaudited.
Cosmos Health said July through October 2026 were the four strongest months to date on Amazon UK, with sales above $215,000 in each month. Monthly sales had risen from approximately $144,000 in November 2025.
Cosmos Health reported that advertising costs represented 2.4% of trailing-twelve-month Amazon UK sales, while refunds remained below 1% of sales. These figures were presented alongside the Company's reported channel-level profitability.
Cosmos Health expects Amazon UK sales to grow by approximately 72% over the next twelve months to approximately $3.9 million, or an average of approximately $325,000 per month. The Company said this outlook is based on current sales trends and planned growth initiatives on the platform, and its release warned that actual results may differ materially.
Cosmos Health said Amazon UK has become an integral part of its transition to a high-margin business model. The Company believes the channel's performance demonstrates the level of profitability its proprietary brands can achieve through efficient online channels.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group with proprietary pharmaceutical and nutraceutical brands. Through its subsidiaries, it manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices, distributes pharmaceuticals and parapharmaceuticals, conducts research and development, and operates in telehealth through its acquisition of ZipDoctor, Inc.
Cosmos Health shares are listed on NASDAQ under the ticker symbol COSM. The source identifies the issuer as Cosmos Health Inc. (NASDAQ:COSM).
Cosmos Health said the sales, unit and profit figures are based on its Amazon UK seller platform data and are unaudited, so they may differ from amounts in its financial statements. The Company also said its net profit and net margin are channel-level operating metrics calculated after direct channel costs and before corporate overheads, while U.S. dollar figures were converted from British pounds sterling at the exchange rate as of the date of the release.